National Skin Cancer Action Week 19-25 November 2018

Ahead of this year’s National Skin Cancer Action Week, MMP clinicians and researchers descended on Brisbane for a joint meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research – the world’s largest congress on melanoma with over 1500 delegates from 53 countries.

Tuning the Microbiome Improves Melanoma Immunotherapy Response

A probiotic regimen might be a good addition to patients that receive anti-programmed cell death protein 1 (anti-PD1) immunotherapy drugs, as investigators at The University of Texas MD Anderson Cancer Center and other institutions have just released new data describing how bacteria that reside in the human digestive tract can influence how melanoma responds to […]

Immunosuppression in multiple myeloma may not increase melanoma risk

Although immunosuppression associated with multiple myeloma may not predispose patients to melanoma, other immunosuppressed states may increase melanoma risk, according to recent findings.

Novel Intervention May Improve Fear of Recurrence Among Cancer Survivors

ConquerFear, a theory-guided intervention, improves the fear of cancer recurrence among survivors in comparison with a control intervention, according to a study published in the Journal of Clinical Oncology.

Cancer in the News

Feature Articles

Almost one in four skin biopsies is melanocytic proliferation

(HealthDay)—About one-quarter of skin biopsies are diagnosed as melanocytic proliferation, according to a study published online Nov. 1 in JAMA Dermatology.

Read the full story

Posted in Melanoma In The News, Information

Christchurch woman leads free skin-checks after losing brother to melanoma

Dermatologist Victoria Scott-Lang is one of 8 specialists volunteering to give free skin-checks at the Christchurch Charity Hospital on Saturday.

Read the full story

Posted in Melanoma In The News, Patient Stories

New Adjuvant Therapy Era Builds in Melanoma

For decades, physicians treating patients with melanoma had 1 option with demonstrated efficacy in the adjuvant setting: interferon alfa-2B.

Read the full story

Posted in Melanoma In The News, Information

CBT Pharmaceuticals’ PD-L1 Antibody Shows Promising Anti-Tumor Activity in Preclinical Studies

CBT Pharmaceuticals‘ anti-PD-L1 antibody CBT-502 has shown promising immune activation and inhibition of tumor growth in preclinical models of cancer, according to new preclinical data.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories